Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026

Description:
Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.

Early diagnosis of hypercalcemia by hydration and treatment with agents - to decrease serum calcium concentrations - also known as hypocalcemic drugs can produce symptomatic improvements within three to five days. The scope of hypercalcemia treatment market study is for Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics for treatment of malignancy-related hypercalcemia.

Market Dynamics
Primary factors fuelling demand for hypercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, growing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternatives over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure.

Market Segmentation by Product Type
Based on product type, the market has been segmented into Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics.

Market Segmentation by Distribution Channel
Revenue from the independent pharmacy and drug stores segment is expected to grow at a very fast pace, and contribute significantly towards distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.

Market Value and Forecast
Global hypercalcemia treatment market revenue is projected to expand at a CAGR of 11.2% during forecast period 2016-2026, and a reach a value of US$ 25,230.2 Mn by the end of 2026.

Key Regions
The global hypercalcemia treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016 end, with revenue contribution expected to expand at a CAGR of 11.4% over the forecast period. Also, North America is estimated to witness comparatively faster growth in terms of revenue over the forecast period.

Western Europe hypercalcemia treatment market is expected to register a CAGR of 11.3% in revenue terms over the forecast period. Bisphosphonates segment revenue in the North America hypercalcemia treatment market is expected to register a CAGR of 11.3% over the forecast period, with growth driven by increasing prevalence of cancer and myeloma among the populace in the region.

Key Players
Some key players in the global hypercalcemia treatment market that have been identified in this report include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy's Laboratories Ltd. and Cipla Inc. The report also identifies company-specific strategies related
Contents:

1. Executive Summary

2. Market Introduction
   2.1. Market Definition
   2.2. Market Taxonomy

3. Global Hypercalcemia Treatment Market Analysis Scenario
   3.1. Market Size (US$ Mn) and Forecast
      3.1.1. Market Size and Y-o-Y Growth
      3.1.2. Absolute $ Opportunity

4. Market Dynamics
   4.1. Macro-economic Factors
   4.2. Drivers
      4.2.1. Supply Side
      4.2.2. Demand Side
   4.3. Restraints
   4.4. Opportunity

5. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Product Type
   5.1. Introduction
   5.2. Basis Point Share (BPS) Analysis By Product Type
   5.3. Y-o-Y Growth Projections By Product Type
   5.4. Market Value Forecast By Product Type, 2014-2026
      5.4.1. Bisphosphonates
         5.4.1.1. Clodronate
         5.4.1.2. Etidronate
         5.4.1.3. Ibandronate
         5.4.1.4. Pamidronate
         5.4.1.5. Zoledronic acid
      5.4.2. Calcitonin
      5.4.3. Glucocorticoids
      5.4.4. Denosumab
      5.4.5. Calcimimetics
   5.5. Prominent Trends
   5.6. Market Attractiveness By Product Type

6. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Distribution Channel
   6.1. Introduction
   6.2. Basis Point Share (BPS) Analysis By Distribution Channel
   6.3. Y-o-Y Growth Projections By Distribution Channel
   6.4. Market Value Forecast By Distribution Channel, 2014-2026
      6.4.1. Hospitals
      6.4.2. Clinics
      6.4.3. Independent Pharmacy and Drug Stores
   6.5. Prominent Trends
   6.6. Market Attractiveness By Distribution Channel

7. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Region
   7.1. Basis Point Share (BPS) Analysis By Region
   7.2. Y-o-Y Growth Projections By Region
   7.3. Market Value Forecast By Region
      7.3.1. North America
      7.3.2. Latin America
      7.3.3. Western Europe
      7.3.4. Eastern Europe
      7.3.5. APEJ
      7.3.6. Japan
      7.3.7. MEA
7.4. Market Attractiveness By Country/Region

8. North America Hypercalcemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis By Country
8.1.2. Y-o-Y Growth Projections By Country
8.2. Market Value Forecast By Product Type, 2014-2026
  8.2.1. Bisphosphonates
    8.2.1.1. Clodronate
    8.2.1.2. Etidronate
    8.2.1.3. Ibandronate
    8.2.1.4. Pamidronate
    8.2.1.5. Zoledronic acid
    8.2.2. Calcitonin
    8.2.3. Glucocorticoids
    8.2.4. Denosumab
    8.2.5. Calcimimetics
8.3. Market Value Forecast By Distribution Channel, 2014-2026
  8.3.1. Hospitals
  8.3.2. Clinics
  8.3.3. Independent Pharmacy and Drug Stores
8.4. Market Value Forecast By Country, 2014-2026
  8.4.1. U.S.
  8.4.2. Canada
8.5. Market Attractiveness Analysis
  8.5.1. By Product Type
  8.5.2. By Distribution Channel
  8.5.3. By Country
8.6. Prominent Trends
8.7. Drivers and Restraints: Impact Analysis

9. Latin America Hypercalcemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Product Type, 2014-2026
  9.2.1. Bisphosphonates
    9.2.1.1. Clodronate
    9.2.1.2. Etidronate
    9.2.1.3. Ibandronate
    9.2.1.4. Pamidronate
    9.2.1.5. Zoledronic acid
    9.2.2. Calcitonin
    9.2.3. Glucocorticoids
    9.2.4. Denosumab
    9.2.5. Calcimimetics
9.3. Market Value Forecast By Distribution Channel, 2014-2026
  9.3.1. Hospitals
  9.3.2. Clinics
  9.3.3. Independent Pharmacy and Drug Stores
  9.4.1. Brazil
  9.4.2. Mexico
  9.4.3. Argentina
  9.4.4. Rest Of Latin America
9.5. Market Attractiveness Analysis
  9.5.1. By Product Type
  9.5.2. By Distribution Channel
  9.5.3. By Country
9.6. Prominent Trends
9.7. Drivers and Restraints: Impact Analysis

10. Western Europe Hypercalcemia Treatment Market Analysis and Forecast
12. APEJ Hypercalcemia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2. Market Value Forecast By Product Type, 2014-2026
12.2.1. Bisphosphonates
12.2.1.1. Clodronate
12.2.1.2. Etidronate
12.2.1.3. Ibandronate
12.2.1.4. Pamidronate
12.2.1.5. Zoledronic acid
12.2.2. Calcitonin
12.2.3. Glucocorticoids
12.2.4. Denosumab
12.2.5. Calcimimetics
12.3. Market Value Forecast By Distribution Channel, 2014-2026
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Independent Pharmacy and Drug Stores
12.4. Market Value Forecast By Country, 2014-2026
12.4.1. China
12.4.2. India
12.4.3. ASEAN
12.4.4. Australia & New Zealand
12.4.5. Rest Of APEJ
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country
12.6. Prominent Trends
12.7. Drivers and Restraints: Impact Analysis

13. Japan Hypercalcemia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2. Market Value Forecast By Product Type, 2014-2026
13.2.1. Bisphosphonates
13.2.1.1. Clodronate
13.2.1.2. Etidronate
13.2.1.3. Ibandronate
13.2.1.4. Pamidronate
13.2.1.5. Zoledronic acid
13.2.2. Calcitonin
13.2.3. Glucocorticoids
13.2.4. Denosumab
13.2.5. Calcimimetics
13.3. Market Value Forecast By Distribution Channel, 2014-2026
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Independent Pharmacy and Drug Stores
13.4. Market Attractiveness Analysis
13.4.1. By Product Type
13.4.2. By Distribution Channel
13.5. Prominent Trends
13.6. Drivers and Restraints: Impact Analysis

14. MEA Hypercalcemia Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.2. Market Value Forecast By Product Type, 2014-2026
14.2.1. Bisphosphonates
14.2.1. Clodronate
14.2.1.2. Etidronate
14.2.1.3. Ibandronate
14.2.1.4. Pamidronate
14.2.1.5. Zoledronic acid
14.2.2. Calcitonin
14.2.3. Glucocorticoids
14.2.4. Denosumab
14.2.5. Calcimimetics
14.3. Market Value Forecast By Distribution Channel, 2014-2026
14.3.1. Hospitals
14.3.2. Clinics
14.3.3. Independent Pharmacy and Drug Stores
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. North Africa
14.4.4. Rest Of MEA
14.5. Market Attractiveness Analysis
14.5.1. By Product Type
14.5.2. By Distribution Channel
14.5.3. By Country
14.6. Prominent Trends
14.7. Drivers and Restraints: Impact Analysis

15. Competition Landscape
15.1. Competition Dashboard
15.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
15.3.1. Bayer Pharma AG
15.3.2. Sun Pharmaceutical Industries Ltd.
15.3.3. Mylan N.V.
15.3.4. Pfizer Inc.
15.3.5. Amgen Inc.
15.3.6. Novartis AG
15.3.7. Dr. Reddy's Laboratories Ltd.
15.3.8. Cipla Inc.

16. Assumptions and Acronyms Used

17. Research Methodology

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3978255/](http://www.researchandmarkets.com/reports/3978255/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026
Web Address: http://www.researchandmarkets.com/reports/3978255/
Office Code: SC2GBGLP

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 7500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp